Actinium Pharmaceuticals Inc. (ATNM)’s Financial Results Comparing With Kura Oncology Inc. (NASDAQ:KURA)

As Biotechnology businesses, Actinium Pharmaceuticals Inc. (NYSEAMERICAN:ATNM) and Kura Oncology Inc. (NASDAQ:KURA), are affected by compare. This especially applies to their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Actinium Pharmaceuticals Inc. N/A 0.00 N/A -0.20 0.00
Kura Oncology Inc. 17 0.00 N/A -1.63 0.00

We can see in table 1 the earnings per share, top-line revenue and valuation of Actinium Pharmaceuticals Inc. and Kura Oncology Inc.


Table 2 hightlights the net margins, return on assets and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
Actinium Pharmaceuticals Inc. 0.00% -213.7% -140.7%
Kura Oncology Inc. 0.00% -40% -35.5%

Volatility and Risk

Actinium Pharmaceuticals Inc. has a 1.79 beta, while its volatility is 79.00% which is more volatile than S&P 500. Kura Oncology Inc.’s 150.00% more volatile than S&P 500 which is a result of the 2.5 beta.


1.8 and 1.8 are the respective Current Ratio and a Quick Ratio of Actinium Pharmaceuticals Inc. Its rival Kura Oncology Inc.’s Current and Quick Ratios are 13.8 and 13.8 respectively. Kura Oncology Inc. has a better chance of clearing its pay short and long-term debts than Actinium Pharmaceuticals Inc.

Analyst Recommendations

The table shown features the ratings and recommendations for Actinium Pharmaceuticals Inc. and Kura Oncology Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Actinium Pharmaceuticals Inc. 0 0 0 0.00
Kura Oncology Inc. 0 0 1 3.00

Competitively Kura Oncology Inc. has an average price target of $22, with potential upside of 34.39%.

Insider and Institutional Ownership

The shares of both Actinium Pharmaceuticals Inc. and Kura Oncology Inc. are owned by institutional investors at 17.6% and 70.8% respectively. Actinium Pharmaceuticals Inc.’s share held by insiders are 0.1%. Comparatively, insiders own roughly 0.8% of Kura Oncology Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Actinium Pharmaceuticals Inc. -7.69% -4.98% -21.93% -58.43% -63.91% -39.84%
Kura Oncology Inc. -2.3% -4.59% 28.84% 22.41% -2.45% 36.18%

For the past year Actinium Pharmaceuticals Inc. has -39.84% weaker performance while Kura Oncology Inc. has 36.18% stronger performance.


On 6 of the 7 factors Kura Oncology Inc. beats Actinium Pharmaceuticals Inc.

Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted payload immunotherapeutics for the treatment of advanced cancers. The companyÂ’s proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its lead product candidate is Iomab-B that is in Phase III clinical studies in refractory or relapsed acute myeloid leukemia (AML) patients over the age of 55 for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60; and Actimab-M that is in Phase I clinical trials for patients with relapsed or refractory multiple myeloma. In addition, it utilizes its alpha-particle immunotherapy technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225 that are directed at various cancers that are blood-borne or form solid tumors. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.

Kura Oncology, Inc., a clinical stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The companyÂ’s lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, lower risk myelodysplastic syndromes, and chronic myelomonocytic leukemia. It also develops KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment for patients with tumors that have mutations in, or other dysregulation of, the mitogen-activated protein kinase; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia. The company was founded in 2014 and is headquartered in La Jolla, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.